DK1556494T3 - Bicistronisk vektor, der koder en VEGF og en FGF, samt anvendelse deraf - Google Patents

Bicistronisk vektor, der koder en VEGF og en FGF, samt anvendelse deraf

Info

Publication number
DK1556494T3
DK1556494T3 DK03754321T DK03754321T DK1556494T3 DK 1556494 T3 DK1556494 T3 DK 1556494T3 DK 03754321 T DK03754321 T DK 03754321T DK 03754321 T DK03754321 T DK 03754321T DK 1556494 T3 DK1556494 T3 DK 1556494T3
Authority
DK
Denmark
Prior art keywords
fgf
vegf
well
vector encoding
bicistronic vector
Prior art date
Application number
DK03754321T
Other languages
English (en)
Inventor
Maciej Malecki
Przemyslaw Janik
Malgorzata Przybyszewska
Irena Mostowska-Was
Original Assignee
Zaklady Farm Polpharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zaklady Farm Polpharma Sa filed Critical Zaklady Farm Polpharma Sa
Application granted granted Critical
Publication of DK1556494T3 publication Critical patent/DK1556494T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
DK03754321T 2002-08-05 2003-08-05 Bicistronisk vektor, der koder en VEGF og en FGF, samt anvendelse deraf DK1556494T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL355354A PL195457B1 (pl) 2002-08-05 2002-08-05 Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
PCT/PL2003/000076 WO2004012775A2 (en) 2002-08-05 2003-08-05 Bicistronic vector encoding a vegf and an fgf, use thereof

Publications (1)

Publication Number Publication Date
DK1556494T3 true DK1556494T3 (da) 2007-12-03

Family

ID=31492970

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03754321T DK1556494T3 (da) 2002-08-05 2003-08-05 Bicistronisk vektor, der koder en VEGF og en FGF, samt anvendelse deraf

Country Status (7)

Country Link
EP (1) EP1556494B1 (da)
AT (1) ATE368745T1 (da)
AU (1) AU2003272159A1 (da)
DE (1) DE60315330T2 (da)
DK (1) DK1556494T3 (da)
PL (1) PL195457B1 (da)
WO (1) WO2004012775A2 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1318594C (zh) * 2005-03-02 2007-05-30 首都医科大学 重组人VEGF与bFGF真核表达载体、融合蛋白及其用途
CN100564527C (zh) * 2006-10-23 2009-12-02 中国人民解放军军事医学科学院生物工程研究所 A型肉毒毒素受体结合区Hc基因及其编码蛋白与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
ES2229788T3 (es) * 1998-10-26 2005-04-16 Ludwig Institute For Cancer Research Uso del gen o proteina vegf-c o vegf-d para prevenir la restenosis.
US7029909B1 (en) * 1998-11-20 2006-04-18 Fuso Pharmaceutical Industries, Ltd. Protein expression vector and utilization thereof
DE19910419A1 (de) * 1999-03-10 2000-09-21 Aventis Pharma Gmbh Zielzellspezifische, multivalente Proteine (MVP)
US20020115202A1 (en) * 1999-08-13 2002-08-22 Paul Hallenbeck Adenoviral vectors including dna sequences encoding angiogenic inhibitors
NZ546670A (en) * 1999-11-05 2009-02-28 Univ California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US6979555B2 (en) * 2000-04-25 2005-12-27 Board Of Regents Of The University Of Oklahoma Hyaluronan receptor for endocytosis

Also Published As

Publication number Publication date
ATE368745T1 (de) 2007-08-15
WO2004012775A3 (en) 2004-05-27
DE60315330T2 (de) 2008-05-08
AU2003272159A8 (en) 2004-02-23
WO2004012775A2 (en) 2004-02-12
DE60315330D1 (de) 2007-09-13
AU2003272159A1 (en) 2004-02-23
EP1556494A2 (en) 2005-07-27
PL195457B1 (pl) 2007-09-28
PL355354A1 (en) 2004-02-09
EP1556494B1 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
EG24358A (en) Isoindolin-1-one glucokinase avtivators
GB0109297D0 (en) Vaccine
TNSN03116A1 (en) Pulmonary administration of chemically modified insulin
WO2002072845A3 (en) Salmonella promoter for heterologous gene expression
AU2001294096A1 (en) Adeno-associated virus-mediated delivery of angiogenic factors
ATE465242T1 (de) Exogene angiogene wachstumsfaktoren exprimierende keratinozyten
AU2002213698A1 (en) Needleless syringe for the subcutaneous delivery of therapeutic agents
DE60036537D1 (de) Zusammensetzungen zur gentherapie von diabetes
IL133976A0 (en) Agents for the treatment of skin disorders
IL158155A0 (en) Use of erythropoietin to ameliorate chemotherapy-induced toxicity in vivo
IL145069A0 (en) Pharmaceutical compositions for delivery to an external wall of a body passageway or cavity
ATE344074T1 (de) Verbesserte injektionsvorrichtung
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
DK1556494T3 (da) Bicistronisk vektor, der koder en VEGF og en FGF, samt anvendelse deraf
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
EP1563075A4 (en) HUMANINSULIN EXPRESSIVE PLASMIDE AND METHOD FOR THE PRODUCTION OF HUMANINSULIN THEREWITH
NO20061542L (no) P185neu-Kodende DNA samt terapeutiske anvendelser derav
GB0409559D0 (en) Polypeptide
MY151447A (en) Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
MXPA04004763A (es) Esteres dobles.
DE50310541D1 (de) Proteolyseresistenter aktiver vegf
Brooks What's love got to do with it?
Reynolds Cardiac resynchronization for heart failure: Its time has come
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components